Menu
“It is a great satisfaction to see how, thanks to the partnership with SOPHiA GENETICS and Diagnóstica Longwood, we will be able to transfer into daily workflow the relevant information generated for so many years in the research of CLL using a simple and robust assay.”
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma.”
“Our collaboration with SOPHiA GENETICS has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402. We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment. We look forward for the results of this research enabled by SOPHiA’s unique platform”
Use one universal, automated protocol for robust sequencing across applications.
Precisely detect SNVs, Indels, and CNVs with our proprietary algorithms.
Match cancer genomic profiles to the most up-to date information with OncoPortal™ Knowledge Base.
Quickly prepare comprehensive reports tailored to your needs.
Sensitive SNV and Indel detection
Accurate CNV calling
Robust variant annotation
Analytics feature 4
Confidently interpret the significance of genomic variants in lymphoid malignancies with MOKA™. Our robust annotation algorithm draws from curated databases and uses de novo analytics to provide insights on the likely effects and pathogenicity of genomic variants.
| SOPHiA DDM™ Lymphoma Solution (LYS) - RUO | SOPHiA DDM™ Community CLL Clonality Solution - RUO | |
|---|---|---|
| Associated disorders | B- and T-cell lymphomas such as diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas | Chronic Lymphocytic Leukaemia |
| Genes | 54 genes | 23 genes + IGH rearrangement |
| Target Region Size | 118 Kb | 48 Kb |
| Key Biomarkers | CREBBP, EP300, EZH2, MEF2B, MYD88, MYC, BRAF | IGH rearrangement, TP53, BTK, BCL2, NOTCH1 |
| Sample Type | FFPE, blood, and bone marrow | Blood and bone marrow |
| Starting Material | 50 ng DNA | 200 ng DNA |
| Sequencer Compatibility | Illumina MiSeq® and NextSeq® | Illumina MiSeq®, NextSeq® and MiniSeq™ |
| Library Preparation Time | 1.5 days | 1.5 days |
| Analysis Time from FASTQ | 4 hours | 4 hours |
| Detected Variants | SNVs Indels Gene amplifications (47 genes) |
SNVs Indels CNVs |
“Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent.
We believe our scientific expertise, combined with AI-enabled technologies and data-driven solutions enabled by SOPHiA GENETICS, presents a unique opportunity to fundamentally transform the journey of cancer patients through non-invasive cancer analysis, predictive genomic testing, and effective precision medicine”.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
